Archive · 26 Jul 2025
Aurobindo Pharma Gears for Growth with New Ventures
Aurobindo Pharma, a drug company, is doing well because of a product called gRevlimid.
They are expanding into new areas like making drugs similar to others (biosimilars) and helping other companies make drugs (CDMO).
They also are working on new products, which may help them to grow in the future.
The company is growing in the US, Europe, and other markets.
They are setting up new factories and expect to make more drugs.
The company is planning to launch biosimilars, enter contract manufacturing, and develop new products.
This will help them stay competitive even when some older products lose their sales.
It is a balanced risk and reward opportunity.
Aurobindo Pharma is positioned for growth with strategies in biosimilars, CDMO, and complex products.
The company experienced revenue growth in the US, Europe, and Growth Markets segments from FY23 to FY25.
Aurobindo is expanding its manufacturing base and launching new products to sustain growth, especially in the US.
Long-term drivers include biosimilars, contract manufacturing with Merck, and development of respiratory products and peptides.
The company's valuation is considered fair at 16 times one-year forward earnings, despite execution risks.
- Who
- Aurobindo Pharma, a generics player, is the focus.
- What
- Aurobindo Pharma is implementing strategies for long-term growth by expanding into biosimilars, CDMO, and complex products.
- When
- The company reported growth from FY23 to FY25. Launch of biosimilars is expected in H2FY26, and contract manufacturing operations starting H2FY27.
- Where
- Operations are in the US, Europe, Growth Markets including Indonesia, Canada, South Africa, and China.
- Why
- To ensure higher margins, less volatile revenues, and better valuations, despite execution risks.
Market Risks
Market Opportunities
Short Term vs Long Term
Market Risks
Execution risks are higher, considering new ventures and elongated payoff horizon for the complex products and the markets they serve.
Market Opportunities
The company has set up operations for the medium-term and long-term growth.
- Revenue Growth CAGR (FY23-25)
- 13%
- US Revenue (FY25)
- $1.7 billion
- US Revenue % (FY25)
- 47%
- Europe Revenue % (FY25)
- 26%
- Growth Markets Revenue % (FY25)
- 10%
- Biosimilars Investment
- $400 million
- CMO Capacity
- 15,000 liters (initial)
- Penicillin-G Facility Investment
- ₹2,700 crore